Moderna Stock Is Trading Higher Monday: What's Going On?
I'm PortAI, I can summarize articles.
Moderna, Inc. (MRNA) shares rose 2.73% to $27.28 after the FDA approved its new COVID-19 vaccine, mNEXSPIKE, for seniors and at-risk individuals. The vaccine demonstrated higher efficacy and a similar safety profile compared to the original vaccine in Phase 3 trials. CEO Stéphane Bancel emphasized the importance of this approval in combating COVID-19, which remains a significant public health threat. mNEXSPIKE is expected to be available for eligible populations in the U.S. by the 2025-2026 respiratory virus season, with global regulatory reviews ongoing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments